Boryung files drug application for novel antihypertensive agent

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said on March 3 that it has filed an application of a new antihypertensive drug (fimasartan) to the Korea Food and Drug Administration.

Fimasartan is a novel, non-peptide angiotensin II receptor antagonist with a selective AT1 receptor blockade effect. The angiotensin-II receptor blockers (ARBs) are the dominant dru...